The diagnosis of pulmonary sarcoidosis relies in part on the observation of alveolar CD4 ϩ lymphocytosis. However, this criterion is not fully discriminative because this anomaly is also found in other types of lung diseases. Among other possible distinctive criteria, we investigated the expression of lymphocyte-addressing molecules, which could differ according to the pathophysiology of lung diseases. We investigated CD103 (␣ E ␤7 integrin, CD103-␤7), reported to be both expressed on intra-epithelial lymphocytes in mucosal areas, including bronchi, and possibly involved in the recruitment of alveolar lymphocytes. The expression of CD103 was examined on bronchoalveolar lavage lymphocytes from 93 consecutive patients, including 34 patients with CD4 ϩ lymphocytosis. For all patients, the expression of CD19, CD3, CD4, CD8, CD57, LFA1, DR, and CD103 was assessed by flow cytometry. Sarcoidosis seemed remarkably characterized by the lack of CD103 expression on the predominant CD4 ϩ subset. Statistically significant differences were found between patients with sarcoidosis, with other types of CD4 ϩ lymphocytosis, and with other lung disorders in the CD103 ϩ cell levels and in the CD103/CD4 ratio. Combined use of the CD4/CD8 ratio (Ͼ 2.5) and the CD103/CD4 ratio (Ͻ 0.31) to assess bronchoalveolar lavage lymphocytes is a promising new tool for the diagnosis of sarcoidosis. (Lab Invest 2000, 80:1065-1069.
I
mmune protection of the lungs involves both nonspecific and specific humoral and cellular responses (Jeffery and Corrin, 1984; Nicod, 1999) . The cellular responses are provided by several types of immunocompetent cells, including macrophages, mast cells, eosinophils, neutrophils, and lymphocytes (Kolopp-Sarda et al, 1994; Pabst and Gehrke, 1992; Pabst and Tschernig, 1995) . In normal conditions, as in other mucosal areas, nonspecific and specific immune responses in the lung are efficient and noninflammatory (Brandtzaeg, 1996; Jeffery and Corrin, 1984; Samet and Utell, 1991) , and only small numbers of lymphocytes are present in lung alveoli. In respiratory diseases, inappropriate or ill-regulated immune responses may develop, involving the bronchi, lung parenchyma, and, in some instances, alveoli (Agostini et al, 1993) .
The widely used technique of bronchoalveolar lavage (BAL) is the least invasive tool to assess the immune status of the lung, and aids in the diagnosis and/or prognosis of respiratory diseases (Agostini et al, 1993; Poulter et al, 1992; Semenzato, 1991) . In normal individuals, BAL have low cell counts and more than 90% of the cells are macrophages (Merchant et al, 1992) . In BAL from patients with lung diseases, the global cell count is often increased, and BAL lymphocytes and/or polymorphonuclears may be present in large proportions. The clinical use of BAL in the diagnosis of lung pathologies is directly related to the cell count and immunophenotype of the BAL lymphocytes (Agostini et al, 1993) . Anomalies detected in BAL may allow early or confirmatory diagnosis and/or prognostic information (Agostini et al, 1993; Poulter et al, 1992) .
BAL hyperlymphocytosis, observed in viral infections, some forms of alveolitis, interstitial syndromes, and sarcoidosis (Agostini et al, 1993; Poulter et al, 1992; Semenzato, 1991) , may involve different T cell subsets. CD4 ϩ cells represent the major T cell subset in most cases of sarcoidosis, and the demonstration of an increased CD4/CD8 ratio has been proposed as a diagnostic tool for pulmonary sarcoidosis. This criterion has been criticized because CD4 ϩ lymphocytosis may also be observed in other types of lung diseases (Agostini et al, 1993) , and although the specificity of an elevated CD4/CD8 ratio is high in sarcoidosis, the sensitivity of this marker is seldom more than 50% (Costabel, 1997; Costabel et al, 1992) .Thus far, the search for other pathognomonic criteria allowing the discrimination of sarcoidosis patients from patients with CD4 ϩ alveolar lymphocytosis has been disappointing.
The mechanisms by which T cells reach lung alveoli, although not well known (Krug et al, 1998; Pabst and Tschernig, 1995) , are likely to depend upon specific addressing signals. Because the respiratory tract is part of the mucosal immune system (Krug et al, 1998; Pabst and Tschernig, 1995) , the addressing signals could involve CD103 (␣ E ␤7 integrin, CD103-␤7) (Cepek et al, 1995; Cerf-Bensussan et al, 1987) , which was first described on human gut intra-epithelial lymphocytes. CD103 has also been reported to be expressed on lymphocytes located in the epithelium of mammary glands, the uterus, bronchi, and bronchial glands (Cepek et al, 1995; Cerf-Bensussan et al, 1987) . CD103 could be involved in the recruitment of lymphocytes to or through lung epithelial cells , as is suggested by a study performed with five healthy subjects, demonstrating the expression of CD103 on 69% of CD8 ϩ and 29% of CD4 ϩ BAL lymphocytes (Erle et al, 1994) . If CD103 is involved in transcytosis, these proportions might be modified in patients with CD4
ϩ alveolar lymphocytosis, perhaps in different fashions depending on the pathophysiology of the disease.
We investigated this hypothesis in 93 consecutive BAL samples sent for immunophenotyping to our laboratory, and found evidence that this surface marker is a discriminative tool for the diagnosis of sarcoidosis in patients with CD4 ϩ lymphocytosis.
Results
Comparison of BAL lymphocytosis showed significant differences between patients and controls ( Table 1) . Group 1 patients had the highest proportions of lymphocytes. The mean percentages of all lymphocyte subsets investigated in each group of patients were compared with those of controls. As expected, major differences were noted for CD4 and CD8 subsets. Patients in both Groups 1 and 2 differed significantly from controls and from Group 3 patients ( p Ͻ 0.0001 for both CD4 and CD8). CD4/CD8 ratios (mean Ϯ SD) were significantly higher in Groups 1 (8.9 Ϯ 5.5) and 2 (5.9 Ϯ 3.0) than in Groups 3 (1.1 Ϯ 0.6) and 4 (1.3 Ϯ 0.5) ( p Ͻ 0.0001). The mean percentage of LFA1 was significantly higher in patients compared with controls ( p Ͻ 0.05). No differences in CD57 or DR expression were found between the four groups. CD19 ϩ lymphocytes were never observed.
Similar proportions of CD103 ϩ cells were observed in Groups 2, 3, and 4 ( Fig. 1 ). This was in sharp contrast with the significantly lower proportion of this subset in Group 1 ( p Ͻ 0.0001 for all comparisons of Group 1 with each of the three other groups). Comparing the level of CD103 expression in sarcoidosis BAL with all other patients (pool of Groups 2, 3, and 4, n ϭ 75), we observed a statistically significant difference ( p Ͻ 0.0001) between sarcoidosis (9.5 Ϯ 6.0%) and all other BAL (33.8 Ϯ 17.1%).
Because five patients in whom the diagnosis of sarcoidosis had been excluded had CD103
ϩ levels within the range of sarcoidosis patients (less than 16%), we examined the CD103/CD4 ratio. As shown in Figure 2 , this ratio significantly discriminates between the four groups of patients tested. Sarcoidosis patients were statistically different from each of the three other groups ( p Ͻ 0.0001). Patients with CD4
ϩ lymphocytosis of other etiology also differed both from Group 3 patients ( p Ͻ 0.01) and from controls ( p ϭ 0.005). Group 3 patients had similar CD103/CD4 values to controls.
According to these results, a CD103/CD4 ratio threshold to be discriminative for sarcoidosis was set at the mean ϩ 2 SD of Group 1, ie, 0.31. All sarcoidosis patients fulfilled this criterion. Only one patient from Group 2 had a CD103/CD4 ratio below 0.31. The only patient in Group 3 who had a CD4/CD8 ratio of 2.6 did not meet the criterion for lymphocytosis (8% of BAL cells) and had a CD103/CD4 ratio of 0.65. The combined sensitivity of a CD103/CD4 ratio Ͻ 0.31 and CD4 ϩ lymphocytosis (defined as a CD4/CD8 ratio Ն 2.5) was 96% for the diagnosis of sarcoidosis.
Discussion
This study reports on BAL lymphocyte immunophenotyping and demonstrates the effective use of CD103 expression as an additional discriminative tool to distinguish sarcoidosis patients from patients with CD4 ϩ lymphocytosis. Indeed, CD4 ϩ lymphocytosis, one of the major characteristics of sarcoidosis, can also be observed in other lung diseases (Agostini et al, 1993) , as was the case in the 16 patients from Group 2 reported here. In this population of non-sarcoidosis patients, the expression of CD103 was noted on 32.8 Ϯ 3.7% of lymphocytes, ie, at least 30% of CD4 ϩ cells, whereas CD4 ϩ lymphocytes from sarcoidosis patients almost completely lacked CD103 expression.
According to previously reported criteria (reviewed in Costabel, 1997; Costabel et al, 1992) , a diagnosis of sarcoidosis could have been suspected in 16 of 18 of the sarcoidosis patients based on a CD4/CD8 ratio more than 3.5, but this was also the case for 12 of 16 of the patients with CD4
ϩ lymphocytosis of a different etiology. Therefore, a correct diagnosis of sarcoidosis 
Sarcoidosis
CD4ϩ Lymphocytosis Other Pathologies Controls % lymphocytes 37.1 Ϯ 3.9*** 30.5 Ϯ 3.6*** 27.9 Ϯ 3.1** 8.5 Ϯ 1.2 % CD3 72.0 Ϯ 3.9** 64.3 Ϯ 3.5* 62.9 Ϯ 2.8 53.4 Ϯ 4.2 % CD4 63.2 Ϯ 3.4*** 54.9 Ϯ 4.4*** 29.9 Ϯ 2.2 28.2 Ϯ 3.2 % CD8 8.7 Ϯ 0.9*** 10.9 Ϯ 1.2*** 31.0 Ϯ 2.0 24.1 Ϯ 2.5 % CD57 8.7 Ϯ 0.9 6.6 Ϯ 1.7 6.9 Ϯ 1.0 4.4 Ϯ 1.2 % CD103 9.5 Ϯ 1.4*** 32.8 Ϯ 3.7 35.4 Ϯ 2.6 28.5 Ϯ 3.6 % LFA1
69.4 Ϯ 3.9** 62.9 Ϯ 3.6* 63.9 Ϯ 2.6* 51.5 Ϯ 4.9 % DR 16.1 Ϯ 5.5 7.7 Ϯ 1.9 13.7 Ϯ 2.3 8.3 Ϯ 2.2 *** p Ͻ 0.0001; ** p Յ 0.01; * p Ͻ 0.05. Statistically significant differences indicated relate to comparison with the control group.
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could only have been achieved in 47% of this series of CD4 ϩ lymphocytosis patients, ie, with a sensitivity similar to that reported in the literature. Combined use of the criteria proposed here, a high CD4/CD8 ratio (Ն 2.5) and a low CD103/CD4 ratio (Ͻ 0.31), allowed a correct diagnosis on BAL in all of the sarcoidosis patients in this study, with a sensitivity of 96%.
This study also investigated whether CD103 could be an addressing molecule involved in the recruitment of BAL lymphocytes in lung diseases. Our data indicate that this hypothesis can be considered for approximately 30% of BAL lymphocytes, except in sarcoidosis.
Two explanations can be proposed for the lack of CD103 on sarcoidosis BAL lymphocytes. First, there could be a down-regulation of CD103 expression after the cells passed through the pneumocytes or bronchial epithelium. This type of mechanism has been reported for CD62L, the L-selectin, which guides peripheral blood lymphocytes to and through high endothelial venules and then disappears from relocated lymphocytes (Chen et al, 1995) . This explanation is unlikely because at least 30% of BAL lymphocytes retain this molecule in other lung diseases. Second, because CD103 is a specific molecule of the mucosal immune system (Cerf-Bensussan et al, 1987) , it could be that CD4 ϩ BAL lymphocytes in sarcoidosis do not originate from mucosal inductive sites. This hypothesis is supported by the sarcoidosis model proposed by Semenzato (1991) suggesting T cell redistribution from the peripheral blood and compartmentalization in the lung. Decreased levels of peripheral CD4 ϩ lymphocytes parallel to increased levels of CD4 ϩ BAL lymphocytes have been described in sarcoidosis (Chailleux et al, 1985) . The absence of CD103 on CD4
ϩ BAL lymphocytes in sarcoidosis would be consistent with a peripheral origin of these cells (CerfBensussan et al, 1987 ). An alternative adhesion molecule that could be used by peripheral lymphocytes to relocate in the lung is the ␣ L ␤ 2 integrin LFA1 (CD11a/ CD18) (Erle et al, 1994; Krug et al, 1998) , and we indeed observed significantly higher proportions of LFA1 ϩ cells in sarcoidosis. From these data, it can be hypothesized that BAL lymphocytes originate from the systemic compartments of peripheral blood in sarcoidosis, and use LFA1 as addressing molecule. In other lung diseases, a mucosal origin for BAL lymphocytes could be suspected, with CD103 ϩ lymphocytes relocating from mucosal areas into the lung and eventually proliferating in response to local stimuli (Chilosi et al, 1988) . 
Individual levels of CD103
ϩ lymphocytes in bronchoalveolar lavage from the four groups of subjects tested. Box whiskers indicate the 25 th and 75 th percentiles (box), mean (horizontal bar), and the 5 th and 95 th percentiles (vertical topped bars).
Figure 2.
Comparative mean levels (topped by SE) of the CD103/CD4 ratio among bronchoalveolar lavage lymphocytes in patients of the four groups studied. Statistical significance is shown for comparisons with the group of sarcoidosis patients (** p Ͻ 0.0001).
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Numerous studies have attempted to identify discriminative markers of sarcoidosis on lung and BAL lymphocytes, and although examinations of the membrane expression of CD25, DR, CD29, VLA-1, and CD2 have been reported, none of these features seemed to be specific for sarcoidosis (Agostini et al, 1993; Krug et al, 1998; Poulter et al, 1992) . Macrophages seem to have a peculiar immunophenotype in sarcoidosis, but are not classically examined in flow cytometry (Poulter et al, 1992) . Increased IL1, IL2, and IFN␥ levels have been reported, but again, these are difficult to assess as a routine diagnostic (Poulter et al, 1992) . Our data demonstrate that the combined use of CD4/CD8 and CD103/CD4 ratios provides a highly sensitive indicator of sarcoidosis in patients with CD4
ϩ BAL lymphocytosis.
Materials and Methods

Patients
Ninety-three consecutive BAL samples addressed to our hospital laboratory for immunophenotyping were included in this study. Lymphocytosis was diagnosed for patients with lymphocytes being more than 10% of BAL cells; CD4 ϩ lymphocytosis was diagnosed when the CD4/CD8 ratio was Ն 2.5.
Subsequent review of clinical and other diagnostic criteria in the patients' medical records allowed partition of the patients into four groups (Table 2) . Group 1 (sarcoidosis) contained 18 patients with CD4
ϩ lymphocytosis and confirmed pulmonary sarcoidosis according to clinical, radiological, and pathology criteria; Group 2 (CD4 ϩ lymphocytosis) contained 16 patients presenting with CD4 ϩ lymphocytosis in whom a diagnosis of sarcoidosis was excluded; Group 3 (other pathologies) contained 48 patients without CD4 ϩ lymphocytosis presenting various types of lung pathologies or abnormal chest X-rays; and Group 4 (controls) contained 11 patients for whom BAL was prescribed on the basis of nonspecific clinical signs but was found to be normal (lymphocytes Ͻ 10%, polymorphonuclear cells Ͻ 5%).
Immunophenotyping
All BAL samples were tested on the day of bronchoalveolar lavage, within 4 hours of collection, using the aliquot of recovered liquid sent for cell count and immunophenotyping to the Immunology laboratory. After centrifugation at 600 ϫ g for 10 minutes, the cell pellet was resuspended in 1 ml of Hanks' medium (Imperial Laboratories, Abdington, United Kingdom). Cell suspensions were adjusted to 10 7 cells/ml. Differentials were performed after cytocentrifugation (Cytospin2; Shandon, Pittsburgh, Pennsylvania) and MayGrü nwald Giemsa staining (Diff Quick; Baxter Dade, Dudingen, Switzerland). The proportions of macrophages, lymphocytes, neutrophils, and eosinophils were evaluated as percentages of total cell numbers.
Immunophenotyping was performed using 50 l aliquots of each cell suspension and monoclonal antibodies directed to CD19 (B4; Coulterclone, Coulter Corporation, Hialeah, Florida), CD3 (T3; Coulterclone), CD4 (T4; Coulterclone), CD8 (T8; Coulterclone), CD57 (NC1; Immunotech, Marseille, France), LFA1 (IOT16; Immunotech), DR (I0.2; Coulterclone), and CD103 (2G5; Immunotech). After labeling, the samples were fixed in 300 l of 1% paraformaldehyde in PBS and processed for flow cytometry using a Coulter XL (Coultronics, Hialeah, Florida). 10M/6F CD4ϩ lymphocytosis, exclusion of a pulmonary sarcoidosis diagnosis. Infectious pneumonitis (n ϭ 3), drug-induced pneumonitis (n ϭ 1), T. canii pulmonary infection (n ϭ 1), histiocytosis X (n ϭ 1), asbestosis (n ϭ 1), extrinsic allergic alveolitis (n ϭ 1), asthma (n ϭ 1), tuberculosis (n ϭ 1) Wegener granuloma (n ϭ 1), auto-immune disease (n ϭ 1), eosinophilic pleurisy (n ϭ 1), inconclusive (n ϭ 3). Other pathologies (Group 3) n ϭ 48 1-88 (54.2 Ϯ 17.3) 34M/14F Absence of CD4 lymphocytosis aspergillosis (n ϭ 1), Hodgkin's lymphoma (n ϭ 1), tuberculosis (n ϭ 1), drug-induced pneumonitis (n ϭ 2), bronchial diseases (n ϭ 2), extrinsic allergic alveolitis (n ϭ 3), systemic diseases (n ϭ 3), chemotherapy (n ϭ 3), extrapulmonary sarcoidosis (n ϭ 3), rheumatoid arthritis (n ϭ 4), asthma (n ϭ 3), respiratory distress (n ϭ 6), infectious pneumonitis (n ϭ 5), interstitial syndrome (n ϭ 11). Controls (Group 4) n ϭ 11 7-85 (42.7 Ϯ 22.4) 6M/5F Controls. Normal BAL prescribed on the basis of suspect chest X-ray.
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Collected events were gated on the lymphocyte window using a morphology scattergram. Results were expressed as the percentage of lymphocytes expressing each of the membrane markers investigated.
Statistical Analysis
Quantitative data were fed to a PC computer using Microsoft Excel and GraphPad Prism (version 2.01; GraphPad Software Inc, San Diego, California) for statistical comparison between the different groups using Kolmogorov-Smirnov, ANOVA, and Student's t test.
